Featured Research

from universities, journals, and other organizations

TB drug could reduce mortality for multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) cases

Date:
September 27, 2012
Source:
European Lung Foundation
Summary:
Results from an observational study evaluating a new anti-TB drug have found that the treatment can improve outcomes and reduce mortality among patients with both MDR-TB and XDR-TB.

Results from an observational study evaluating a new anti-TB drug have found that the treatment can improve outcomes and reduce mortality among patients with both MDR-TB and XDR-TB.

The research, published online ahead of print today (27 September 2012) in the European Respiratory Journal, suggests a drug called delamanid could have a public health benefit for MDR-TB and also for XDR-TB, as few effective treatment options are currently available.

Over the past two decades, multidrug-resistant TB (MDR-TB) has emerged as a significant public health threat, with strains of TB growing increasingly resistant to first-line drugs. MDR-TB hampers progress towards the global elimination of TB and recently it has further evolved into an even more resistant form, called extensively drug-resistant tuberculosis (XDR-TB).

The WHO Global Plan to Stop TB 2011-2015 has called for urgent development of new drugs with novel mechanisms of action to treat all forms of TB, including MDR and XDR-TB.

A randomised control trial has previously evaluated the effectiveness of 2 months treatment with different doses of the drug. The new study followed the same patients and observed the outcomes of their treatment for a further 24 months.

421 patients took part in the observational study and researchers examined the effects of delamanid when taken in combination with a World Health Organization-recommended background treatment regimen. The researchers classified the patients into either a favourable outcomes group, where the patient was cured or completed the treatment, or an unfavourable outcome, where the patient had failed the treatment course, defaulted or died.

The results found that 74.5% of patients taking delamanid for more than 6 months had favourable outcomes. This compared to 55% of patients taking the drug for less than 2 months. Furthermore, only two patient deaths occurred in the long-term group, compared to 19 in the short-term treatment group.

In the subset of patients suffering with XDR-TB, 61.4% of patients in the long-term group experienced favourable outcomes, compared with 50% in the short-term group. Mortality was also reduced within this subset.

Lead author, Vija Skripconoka from the Riga East University Hospital, said: "The observational study has shown that when delamanid is taken for at least 6 months with a WHO-recommended background treatment regimen, it can improve outcomes for patients with MDR-TB and XDR-TB. This is extremely positive news given that similar studies of different treatments rarely report favourable outcomes above 70% or mortality rates below 15%. The 1% mortality rate measured in this study is very promising. A further randomised-control study is currently enrolling a large group of people to confirm delamanid's effectiveness and monitor side-effects."


Story Source:

The above story is based on materials provided by European Lung Foundation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vija Skripconoka, Manfred Danilovits, Lea Pehme, Tarmo Tomson, Girts Skenders, Tiina Kummik, Andra Cirule, Vaira Leimane, Anu Kurve, Klavdia Levina, Lawrence Geiter, Davide Manissero, Charles D. Wells. Delamanid Improves Outcomes and Reduces Mortality for Multidrug-Resistant Tuberculosis. European Respiratory Journal, 2012; DOI: 10.1183/09031936.00125812

Cite This Page:

European Lung Foundation. "TB drug could reduce mortality for multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) cases." ScienceDaily. ScienceDaily, 27 September 2012. <www.sciencedaily.com/releases/2012/09/120926213755.htm>.
European Lung Foundation. (2012, September 27). TB drug could reduce mortality for multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) cases. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2012/09/120926213755.htm
European Lung Foundation. "TB drug could reduce mortality for multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) cases." ScienceDaily. www.sciencedaily.com/releases/2012/09/120926213755.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WHO Calls for Ban on E-Cigarette Sales to Minors

WHO Calls for Ban on E-Cigarette Sales to Minors

AFP (Aug. 26, 2014) The World Health Organization called Tuesday on governments should ban the sale of e-cigarettes to minors, warning that they pose a "serious threat" to foetuses and young people. Duration: 01:44 Video provided by AFP
Powered by NewsLook.com
Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com
Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Newsy (Aug. 26, 2014) A new study found fewer deaths from prescription drug overdoses in states that have legalized medical marijuana. But experts disagree on the results. Video provided by Newsy
Powered by NewsLook.com
Official: British Ebola Sufferer Receiving Experimental Drug

Official: British Ebola Sufferer Receiving Experimental Drug

AFP (Aug. 26, 2014) A British nurse infected with Ebola while working in Sierra Leone is being given the same experimental drug used on two US missionaries who have recovered for the disease, doctors in London say. Duration: 00:44 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins